

Organizer:



Collaborating  
Organization:



Supporting  
Organization:

**croucher**

Secretariat:



# MOUNT HOOD DIABETES HEALTH ECONOMICS CONFERENCE IN CLINICAL DECISION MAKING 2024 – HONG KONG

**23–24 NOVEMBER 2024 | HONG KONG**



**Date :**

23 – 24 November 2024

**Abstract deadline:**

27 September 2024

**Conference mode:**

In-person



**Hong Kong**

Lecture Theatre LT1,  
Henry Cheng International Conference Centre,  
1/F Cheng Yu Tung Building  
The Chinese University of Hong Kong  
Shatin, New Territories  
Hong Kong

This conference aims to enhance multi-sectoral exchanges and capacity building on the adoption of health economic evaluation and modelling in diabetes and related chronic diseases to align with international health technological assessment (HTA) standards.

*Mark your diary!*

Visit our Website

<https://mounthood2024.mect.cuhk.edu.hk>

Email Us

[mthood2024@cuhk.edu.hk](mailto:mthood2024@cuhk.edu.hk)

Call Us

+852 3505 1419

Mount Hood Diabetes Health  
Economics Conference in Clinical  
Decision Making 2024



## DAY 1 (23 NOVEMBER 2024 )

08:15 - 09:00	<b>Registration</b>	
09:00 - 11:00	<b>Introductory workshop 1</b> An overview of health economic diabetes simulation models and its application in a clinical setting for healthcare professionals	Prof Philip Clarke
11:00 - 11:20	<b>Break</b>	
11:20 - 12:30	<b>Oral presentation 1</b> <ul style="list-style-type: none"> <li>Diabetes risk prediction simulation model development and validation</li> <li>Artificial intelligence and health economic evaluation</li> </ul>	Chairpersons: Dr Jianchao Quan Dr Tina Lian
12:30 - 13:30	<b>Lunch</b>	
13:30 - 14:30	<b>Malaysia Mount Hood challenge meeting modelling results discussion and its implications to real-world clinical decision making in Asia</b>	Chairperson: Dr Juliana Lui  Panelists: Dr Phil McEwan Dr Michael Willis Prof Philip Clarke Dr An Duy Tran
14:30 - 15:40	<b>Oral presentation 2</b> <ul style="list-style-type: none"> <li>Healthcare economic burden of diabetes and NCDs</li> <li>Economic evaluation in diabetes and NCD management</li> <li>Patient preferences in diabetes and NCD management</li> </ul>	Chairpersons: Dr Richard Xu Dr Wai Kit Ming
15:40 - 16:00	<b>Break</b>	
16:00 - 18:00	<b>Introductory workshop 2</b> Understanding your patient and their healthcare preferences better utilizing discrete choice experiments	Dr John Buckell

## DAY 2 (24 NOVEMBER 2024 )

08:15 - 09:00	<b>Registration</b>	
09:00 - 09:05	<b>Welcome and opening remarks</b>	Prof Philip Clarke
09:05 - 09:15	<b>Opening Ceremony</b> <b>Guest of Honour</b>	Prof Philip Chiu
09:15 - 09:40	<b>Opening plenary</b> Challenges in long-term diabetes risk prediction modelling - balancing real-world data and randomized controlled trials	Prof Philip Clarke
<b>Symposium 1 (Chairperson: Dr Lee Ling Lim and Dr Juliana Lui)</b>		
09:40 - 10:05	Deliver of a sustainable diabetes management in evolving primary care system in Hong Kong	Dr Fei Chau Pang
10:05 - 10:30	Applying health economics modelling for national-level interventions in diabetes and non-communicable diseases and its implications to clinical practice - insights from the USA healthcare perspective	Dr Ping Zhang
10:30 - 10:55	Harnessing the potential of artificial intelligence in diabetes and non-communicable disease risk prediction modelling	Dr Hui Shao
10:55 - 11:15	<b>Break</b>	

## DAY 2 (24 NOVEMBER 2024)

11:15 – 11:45	<b>Mini discussion panel 1</b> Discussion on challenges in diabetes risk prediction simulation modelling considering Asian and Western patient population differences	Moderators: Prof Michael Willis Dr Phil McEwan Dr An Duy Tran
<b>Symposium 2 (Chairpersons: Dr Jianchao Quan and Dr Benjamin Yip)</b>		
11:45 – 12:10	Applying health economics modelling for national-level interventions in diabetes and non-communicable diseases and its implications to clinical practice – insights from the UK healthcare perspective	Prof Amanda Adler
12:10 – 12:35	The value-based pricing paradigm for pharmaceutical drugs: how it drives clinical decision making, patient benefits and affordable solutions	Prof Huang Tz Ou
12:35 – 13:00	Applying health economics modelling for national-level interventions and drug reimbursement policies in diabetes and non-communicable disease and its implications to clinical practice – insights from the Chinese healthcare perspective	Dr Jenny Zhang
13:00 – 14:00	<b>Lunch</b>	
<b>Symposium 3 (Chairpersons: Dr Elaine Chow Prof Joyce You)</b>		
14:00 – 14:30	The Role of Cost-effectiveness in Drug Formulary new drug enlistment procedures – Insights from Hong Kong	Dr Carlos Wong
14:30 – 14:55	Advancing Health Economics in Asia: The Malaysian Health Technology Assessment Section (MaHTAS) Journey Towards Stronger Health Technology Assessment in Malaysia	Dr Izzuna Mudla Mohamed
14:55 – 15:15	Cost-effective treatment and management of patients with diabetes and non-communicable diseases in Greater Bay Area	Prof Haipeng Xiao
15:15 – 15:35	Importance of cost-effectiveness analysis in health technological assessment to clinical practice and optimal healthcare resource allocation in Asia	Dr Jarawee Sukmanee
15:35 – 15:55	Long-term cost-effectiveness of novel non-steroidal mineralocorticoid antagonists as renal protective drugs in Chinese patients with type 2 diabetes and chronic kidney disease: application of the Chinese diabetes outcomes model (CDOM)	Dr Juliana Lui
15:55 – 16:15	<b>Break</b>	
16:15 – 17:50	<b>Advancing Asian Health Economics for Diabetes and Metabolic Non-Communicable Diseases (AHEAD) in clinical decision making 1st Multi-sectoral Panel Discussion</b> <ul style="list-style-type: none"> <li>• Prof Juliana Chan</li> <li>• Ms Sabrina Chan</li> <li>• Dr Elaine Chow</li> <li>• Dr Izzuna Mudla Mohamed</li> <li>• Dr Kelvin Tan</li> <li>• Dr Jarawee Sukmanee</li> <li>• Prof Haipeng Xiao</li> <li>• Prof Joyce You</li> </ul>	Moderators: Prof Philip Clarke Dr Juliana Lui
17:50 – 18:00	<b>Closing remarks</b>	Prof Juliana Chan

Funded by:



Acknowledgment:

This material/ event is funded by the Professional Services Advancement Support Scheme of the Government of the Hong Kong Special Administrative Region.

Disclaimer:

Any opinions, findings, conclusions or recommendations expressed in this material/ any event organised under this project do not reflect the views of the Government of the Hong Kong Special Administrative Region or the Vetting Committee of the Professional Services Advancement Support Scheme.